c-Met inhibitor 1Inhibitor of the c-Met receptor CAS# 1357072-61-7 |
2D Structure
- Ki20227
Catalog No.:BCC1678
CAS No.:623142-96-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1357072-61-7 | SDF | Download SDF |
PubChem ID | 56650915 | Appearance | Powder |
Formula | C17H14N8S | M.Wt | 362.41 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 20 mg/mL (55.19 mM; Need ultrasonic) | ||
Chemical Name | 3-(2-methylindazol-5-yl)sulfanyl-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazine | ||
SMILES | CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=CN(N=C5C=C4)C)C=C2 | ||
Standard InChIKey | JYXHZDNTBJUJNH-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H14N8S/c1-23-10-12(8-18-23)15-5-6-16-19-20-17(25(16)22-15)26-13-3-4-14-11(7-13)9-24(2)21-14/h3-10H,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
IC50 value:
Target: c-Met
More details please refer to Patent WO 2012015677 A1. References: |
c-Met inhibitor 1 Dilution Calculator
c-Met inhibitor 1 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7593 mL | 13.7965 mL | 27.5931 mL | 55.1861 mL | 68.9826 mL |
5 mM | 0.5519 mL | 2.7593 mL | 5.5186 mL | 11.0372 mL | 13.7965 mL |
10 mM | 0.2759 mL | 1.3797 mL | 2.7593 mL | 5.5186 mL | 6.8983 mL |
50 mM | 0.0552 mL | 0.2759 mL | 0.5519 mL | 1.1037 mL | 1.3797 mL |
100 mM | 0.0276 mL | 0.138 mL | 0.2759 mL | 0.5519 mL | 0.6898 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Lesinurad is an inhibitor of URAT1 that promoting renal uric acid excretion [1].URAT1 is a transporter in the kidney that regulates uric acid excretion from the body [2].
In the clinical study, lesinurad potently inhibit URAT1 as well as OAT4, another transporter responsible for the renal resorption of urate. In a study, 21 people with hyperuricemia or gout (sUA >= 8.0 mg/dL) were randomized to lesinurad, open-label allopurinol or placebo. Most of the lesinurad-treated patients had sUA < 6 mg/dL after seven days, which were the same effect to patients receiving allopurinol and better than placebo. Also, Lesinurad showed well tolerated in the study [2]. Compared with probenecid, whose efficacy is reducing patients with renal insufficiency, lesinurad may be effective in patients with mildly impaired renal function [1].
References:
[1]. Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med, 2013, 64: 325-337.
[2]. Singh JA. Emerging therapies for gout. Expert Opin Emerg Drugs, 2012, 17(4): 511-518.
- N-Acetylglycyl-D-glutamic acid
Catalog No.:BCC6634
CAS No.:135701-69-8
- HG-14-10-04
Catalog No.:BCC5392
CAS No.:1356962-34-9
- AZD-3463
Catalog No.:BCC3907
CAS No.:1356962-20-3
- ent-3-Oxokaurane-16,17-diol
Catalog No.:BCN6188
CAS No.:135683-73-7
- Narchinol B
Catalog No.:BCN7796
CAS No.:1356822-09-7
- Fmoc-Cha-OH
Catalog No.:BCC3160
CAS No.:135673-97-1
- 17-Methylparsonsianidine
Catalog No.:BCN2093
CAS No.:135637-68-2
- CP 80633
Catalog No.:BCC7463
CAS No.:135637-46-6
- Coccineone B
Catalog No.:BCN6464
CAS No.:135626-13-0
- Fmoc-D-His(Trt)-OH
Catalog No.:BCC3504
CAS No.:135610-90-1
- Parsonsianidine
Catalog No.:BCN2109
CAS No.:135601-81-9
- Pneumocandin B0
Catalog No.:BCC5436
CAS No.:135575-42-7
- ML 228
Catalog No.:BCC2435
CAS No.:1357171-62-0
- MDL 29,913
Catalog No.:BCC5729
CAS No.:135721-56-1
- Palonosetron
Catalog No.:BCC1834
CAS No.:135729-61-2
- Palonosetron hydrochloride
Catalog No.:BCN2171
CAS No.:135729-62-3
- Taxinine M
Catalog No.:BCN6942
CAS No.:135730-55-1
- OG-L002
Catalog No.:BCC4549
CAS No.:1357302-64-7
- Nonin A
Catalog No.:BCN7149
CAS No.:1357351-29-1
- RGFP966
Catalog No.:BCC3991
CAS No.:1357389-11-7
- Boc-Glu(OBzl)-OH
Catalog No.:BCC3389
CAS No.:13574-13-5
- Isoforsythiaside
Catalog No.:BCN5413
CAS No.:1357910-26-9
- Koumine
Catalog No.:BCN6190
CAS No.:1358-76-5
- erythro-Guaiacylglycerol beta-dihydroconiferyl ether
Catalog No.:BCN7025
CAS No.:135820-77-8
Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl] -N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.[Pubmed:23379595]
J Med Chem. 2013 Mar 28;56(6):2294-310.
This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under investigation as a treatment for cancer. The design of 11r was based on the desire to reduce time-dependent inhibition of CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access 11r and analogues. We provide a rationale for the observed selectivity based on X-ray crystallographic evidence and discuss selectivity trends with additional examples. Importantly, 11r provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to c-Met inhibitors without preferential binding to the active kinase conformation.
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl )quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.[Pubmed:23944843]
J Med Chem. 2013 Sep 12;56(17):6651-65.
The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An exclusively selective c-Met inhibitor (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl )quinoline (8) was discovered from a highly selective high-throughput screening hit via structure-based drug design and medicinal chemistry lead optimization. Compound 8 had many attractive properties meriting preclinical evaluation. Broad off-target screens identified 8 as a pan-phosphodiesterase (PDE) family inhibitor, which was implicated in a sustained increase in heart rate, increased cardiac output, and decreased contractility indices, as well as myocardial degeneration in in vivo safety evaluations in rats. Compound 8 was terminated as a preclinical candidate because of a narrow therapeutic window in cardio-related safety. The learning from multiparameter lead optimization and strategies to avoid the toxicity attrition at the late stage of drug discovery are discussed.
Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)q uinoline as a highly potent and selective c-Met inhibitor.[Pubmed:27061987]
Eur J Med Chem. 2016 Jun 30;116:239-251.
c-Met/HGF overexpression has been detected in many human malignancies including tumors which are resistant to anticancer therapy. Disrupting the aberrant c-Met/HGF axis has enjoyed significant progress in both preclinical and clinical antitumor campaign. To eliminate the OCH2-related metabolic deficiency of our previously reported triazolotriazine 2, we synthesized a series of CH2-/CF2-linked triazolotriazines and assessed their c-Met activities, leading to the highly potent compound 23 with IC50 values of 0.24 nM of enzymatic activity in c-Met and 0.85 nM of cellular activity in EBC-1 cancer cell line, as well as with complete tumor regression in EBC-1 xenograft mice model at dose of 25 mg/kg via oral administration. Based on its potent anti-proliferative activities and favorable pharmacokinetic properties, 23 has been selected as a drug candidate for preclinical investigation.
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2, 3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.[Pubmed:25148209]
J Med Chem. 2014 Sep 25;57(18):7577-89.
HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.